Advancing GBA1 Research: A Glimpse into GBA1 Canada’s Mission and Impact GBA1 Canada (G-Can) stands at the forefront of neurodegenerative disease research, focusing on the …
Events and Team Interviews
On April 26, 2025, thousands gathered in New York City’s Central Park for the 31st annual Parkinson’s Unity Walk, a cornerstone event hosted by The …
The world’s leading experts in neurodegenerative diseases gather at the AD/PD Conference (Alzheimer’s Disease and Parkinson’s Disease) to present groundbreaking research, share insights, and discuss …
This September Gain Therapeutics is attending and presenting at two conferences. H.C. Wainwright 26th Annual Global Investment Conference The H.C. Wainwright 26th Annual Global Investment …
Summary: At the Annual Neuro Perspectives Virtual Conference hosted June 27th, H.C. Wainwright hosted a Fireside Chat with Ram Selvaraju, a Senior Healthcare Equity Research …
Parkinson’s disease (PD) remains a significant challenge in neurodegenerative research, with the GBA1 mutation presenting a particularly aggressive form of the disease. Gain Therapeutics is …
The new CFO fills in the missing link When you think of a Chief Financial Officer, the first thing that comes to mind is not …
Part 3 Interview with Jonas Hannestad, MD, PhD – Chief Medical Officer In Part 3 of our discussion with Gain’s Chief Medical Officer Jonas Hannestad, …
Part 2 Interview with Jonas Hannestad, MD, PhD – Chief Medical Officer In Part 2 of our discussion with Gain’s Chief Medical Officer Jonas Hannestad, …
Gain Therapeutics, Inc. reports promising results from its Phase 1 trial of GT-02287, a novel therapy for GBA1 Parkinson’s disease. The study indicates the therapy is safe and well-tolerated, enhancing GCase enzyme function, which is pivotal in combating the disease’s progression.
Meet Gain Therapeutics’ New Chief Medical Officer: Dr Jonas Hannestad, MD, PhD
Explore the innovative world of Gain Therapeutics in this engaging fireside chat held by Lou Basenese and Jeb Terry at the recent Public Ventures Discovery Day event. Delve into how we are revolutionizing the treatment of neurodegenerative diseases, including Parkinson’s, with our next-generation Magellanᵀᴹ platform. Gain harnesses AI and physics-based methods to develop best-in-class small molecules for disorders with high unmet medical needs. Hear about the significant strides we’ve made from current Board Member and former Gain CEO Eric Richman. A must-watch for those interested in the intersection of biotechnology, AI, and healthcare advancements.
Analyzing data from Genome Wide Association Studies (GWAS) and drawing from the insights of the PD GENEration Study, Dr. Alcalay unveils the significance of glucocerebrosidase (GBA) mutations in Parkinson’s. Discover why GBA emerges as a prime target for therapeutic interventions, offering hope for tailored treatments and improved patient outcomes.
Professor Outeiro provides an in-depth exploration of Parkinson’s disease from the perspective of a seasoned basic scientist. Covering topics ranging from disease complexity and classification to emerging biomarkers and therapeutic strategies, he delves into the intricacies of Parkinson’s research, highlighting the challenges faced by scientists and clinicians alike.
Joanne Taylor highlights the groundbreaking work of Gain Therapeutics in developing GT-02287, a GBA modulator, as a potential treatment for Parkinson’s disease. She discusses the origin of GT-02287, its mechanism of action, and preclinical findings demonstrating its efficacy in addressing key pathological features of Parkinson’s disease.
What Makes a Truly Valuable AI Drug Discovery Platform? The value in AI drug discovery platforms lies in their ability to target known, yet previously …
Gain Therapeutics is ready to share the latest R&D update on Parkinson’s Disease. This event is intended for all KOL’s, Analysts, Patient Advocates, and investors …
Watch the video from 50 sec onwards to learn hear about Gain Therapeutics Gain Therapeutics was mentioned on Fox Business News as a company to …
Beatriz Calvo-Flores Guzman, presented at the 20th Annual WORLDSymposium discussing preclinical data demonstrating that our clinical-stage GCase regulator provided neuroprotection & restored motor function in …
This webinar, hosted by Force Family Office, features Gain Therapeutics, a biotech company developing treatments for Parkinson’s disease and other neurodegenerative diseases. The speakers are …
Gain Therapeutics will be attending JP Morgan HealthCare Conference Jan 8th to 11th, 2024 in San Francisco. Representing will be: CEO Matthias Alder CFO Evan …
“The published data propose that strategies to alleviate dysfunction such as targeting GCase could be a new therapeutic opportunity for neurodegenerative diseases and lysosomal storage …
Gain’s Clinical Candidate GT-02287 Earlier this month, Gain Therapeutics announced the dosing of the first two subjects in a Phase 1 clinical trial of GT-02287, …
In an engaging interview, journalist Jane King from LilaMax Media discusses cutting-edge allosteric therapies with Gain Therapeutics’ CEO, Matthias Alder, and their potential in …
On the topic of standards and regulations, what has it been like to work with regulatory agencies such as the FDA and EMA (European Medicines …
“Data! Data! Data! I can’t make bricks without clay.” This famous quote from Sherlock Holmes summarizes Dr. Terenzio Ignoni’s outlook on the future of drug …
Give him the data, give him the facts, and Dr. Terenzio Ignoni will run with them. As the SVP of Technical Operations, Terenzio is in …
We’re back with Ana Maria Garcia-Collazo, Ph.D. of Gain Therapeutics. We ended Part 1 of our interview talking about the intersection of chemistry and computational …
Wisdom is not hard to come by. Passion and enthusiasm are a different story. On a bright and sunny Thursday morning in April 2023, Ana …
Part 2: When we left off speaking to Evan Ballantyne, Gain Therapeutics’ new CFO, he was sharing several stories about industry and career successes. Part …